Tempus Labs, Inc.

Tempus Ai, Inc.

Yilin Zhang

Ameen Salahudeen

Verónica Sánchez Freire

Aly Azeem Khan

Brian M Larsen

Madhavi Kannan

Michelle M Stein

Luka A Karginov

Robert Tell

Joshua S K Bell

Catherine Igartua

Aarti Venkat

Jerod Parsons

Methods, systems, and software are provided for using organoid cultures, e.g., patient-derived tumor organoid cultures, to improve treatment predictions and outcomes.

Systems and methods for predicting therapeutic sensitivity

Large scale organoid analysis

Methods, systems, and software are provided for determining a homologous recombination pathway status of a cancer in a test subject, e.g., to improve cancer treatment predictions and outcomes. In some embodiments, classifiers using one or more of (i) a heterozygosity status for DNA damage repair genes in a cancerous tissue, (ii) a measure of the loss of heterozygosity across the genome of the cancerous tissue, (iii) a measure of variant alleles detected in a second plurality of DNA damage repair genes in the genome of the cancerous tissue, (iv) a measure of variant alleles detected in the second plurality of DNA damage repair genes in the genome of a non-cancerous tissue, and (v) tumor sample purity are provided.

Integrated machine-learning framework to estimate homologous recombination deficiency

Growing community of inventors

Wilmette, IL, United States of America

Yilin Zhang